| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/09/2002 | US20020055635 Cycloalkano-indole and -azaindole derivatives |
| 05/09/2002 | US20020055632 Such as (3R,5S)-1-pyrimidin-2-yl-5-(2,4,5-trifluoro-benzyloxymethyl)-pyrrolidine-3 -thiol trifluoro-acetate useful as inhibitors of metalloproteases for treating diseases associated with vasoconstriction |
| 05/09/2002 | US20020055630 Process for preparation of cyclopenta [b] [1,4] diazepino [6,7,1-hi] indole derivatives |
| 05/09/2002 | US20020055621 Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
| 05/09/2002 | US20020055620 Reduction inhibitory agent for active oxygen eliminating activity |
| 05/09/2002 | US20020055616 Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors |
| 05/09/2002 | US20020055615 Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology |
| 05/09/2002 | US20020055562 Gel compositions |
| 05/09/2002 | US20020055544 Administering tramadol; slower initial titration rate of tramadol which results in a lower percentage of discontinuations of therapy due to a lower incidence and severity of side effects. |
| 05/09/2002 | US20020055543 Inhibit phosphodiesterase type IV or inhibit the production of tumor necrosis factor; useful in treating diseases including asthma, arthritis, and sepsis. |
| 05/09/2002 | US20020055542 E.g., phenylbutyric acid; for treating a subject having an ulcer or radiation fibrosis. |
| 05/09/2002 | US20020055541 Including longistyline A-2-carboxylic acid as a dietary supplement |
| 05/09/2002 | US20020055540 Oral creatine supplement and method for making same |
| 05/09/2002 | US20020055539 Intravascularly administering to the occlusive vascular site an effective amount of an omega fatty acid. |
| 05/09/2002 | US20020055538 Aspirin-triggered lipid mediators |
| 05/09/2002 | US20020055537 Treating a crop infected with a phytopathogenic animal pest; treatment of vertebrates and humans infested by helminths or ectoparasites. |
| 05/09/2002 | US20020055535 Treating hyper-excited sensory nerve functions, comprising administering (2-Amino-4,5,6,7-tetrahydrobenzo(b)thiophen-3-yl)(4-chlorophenyl) methanone or a acceptable salt thereof |
| 05/09/2002 | US20020055534 Method for treating neurodegeneration |
| 05/09/2002 | US20020055533 N-(1-octyl-5-carboxymethyl-4, 6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof, and an HMG-COA reductase inhibitor; prevention or treatment of atherosclerosis or xanthoma |
| 05/09/2002 | US20020055531 Methods for treatment of inflammatory diseases |
| 05/09/2002 | US20020055530 Diphenyl sulfides, diphenyl sulfoxides, diphenyl sulfones, and sulfide, sulfoxide and sulfones of dibenzothiophene and thioxanthene |
| 05/09/2002 | US20020055529 Method for treating alzheimer's disease |
| 05/09/2002 | US20020055527 Thiazolium compounds and treatments of disorders associated with protein aging |
| 05/09/2002 | US20020055526 Modulators of SKCa, IKCa and BKCa channels. |
| 05/09/2002 | US20020055524 Novel aryl substituted tetrahydroindazoles as ligands of the GABA receptor |
| 05/09/2002 | US20020055523 Inhibiting a PTPase treating type 1 and 2 diabetes, insulin resistance and pathological obesity |
| 05/09/2002 | US20020055521 Analogs of cocaine |
| 05/09/2002 | US20020055520 Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist |
| 05/09/2002 | US20020055518 Polyoxyethylated hydroxyesters of rapamycin useful in inducing immunosuppression and in the treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease. |
| 05/09/2002 | US20020055517 Methods for delaying recurrence of herpes virus symptoms |
| 05/09/2002 | US20020055516 Nitrogen-containing heterocyclic compounds and medicaments containing the compounds |
| 05/09/2002 | US20020055515 Contacting stimulated cells with a candidate compound which is an inhibitor of ATP binding to a P2Y- purinoceptor; and assaying said cells for release of one or more mediators. |
| 05/09/2002 | US20020055514 JAK-3 inhibitors for treating allergic disorders |
| 05/09/2002 | US20020055512 Release rate controlling substance; treating metabolic syndrome, diabetes mellitis type II or symptoms |
| 05/09/2002 | US20020055510 Useful in the treatment of cancer. |
| 05/09/2002 | US20020055508 Benzofurazan compounds which enhance AMPA receptor activity |
| 05/09/2002 | US20020055507 Ureas and thioureas inhibit production of cytokines |
| 05/09/2002 | US20020055506 Methods for treatment of disease-induced peripheral neuropathy and related conditions |
| 05/09/2002 | US20020055505 Sultam and sultone derived oxazolidinones |
| 05/09/2002 | US20020055504 Acylating a cyclopentaindolemethylamine and cyclizing and reducing the product |
| 05/09/2002 | US20020055503 Treatment of seizures resulting from, e.g. epileptic attack. |
| 05/09/2002 | US20020055501 Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. |
| 05/09/2002 | US20020055500 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds |
| 05/09/2002 | US20020055497 Method for treating allergies using substituted pyrazoles |
| 05/09/2002 | US20020055496 Formulation and system for intra-oral delivery of pharmaceutical agents |
| 05/09/2002 | US20020055495 Two-component anti-emetic composition |
| 05/09/2002 | US20020055494 Combinations of formoterol and mometasone furoate for asthma |
| 05/09/2002 | US20020055493 Phytosterol and/or phytostanol derivatives |
| 05/09/2002 | US20020055491 Administering fosfomycin or a pharmaceutically acceptable salt thereof in an effective dose to lower the serum glucose level in blood. |
| 05/09/2002 | US20020055490 Medicament |
| 05/09/2002 | US20020055489 Interleukin-12 inducer and medical composition |
| 05/09/2002 | US20020055488 Prevention and treatment of streptococcal and staphylococcal infection |
| 05/09/2002 | US20020055487 Inhibitor of an enzyme having beta -glucosidase activity, or a glycosphingolipid, particularly glucocerebroside |
| 05/09/2002 | US20020055486 Pharmaceutical composition for ophthalmic use |
| 05/09/2002 | US20020055485 Method of treating arrhythmias |
| 05/09/2002 | US20020055484 Methods for modulating the axonal outgrowth of central nervous system neurons |
| 05/09/2002 | US20020055483 Treating hepatitus B, C and D; AIDS; antiproliferative agents |
| 05/09/2002 | US20020055482 Molecular constructs with a carcinoembryonic antigen (cea) transcriptional regulatory sequence |
| 05/09/2002 | US20020055479 Treating type 2 diabetes, metabolic disorders, obesity and cancer. |
| 05/09/2002 | US20020055478 Monitoring 103P3E8 gene products in a biological sample from a patient who has or who is suspected of having cancer and comparing the gene expression products with that of a normal sample |
| 05/09/2002 | US20020055477 Immunomodulatory formulations and methods for use thereof |
| 05/09/2002 | US20020055475 Cytidylyl(3'-->5')guanosine ammonium salt (CpG); reducing the immunostimulatory effect for antisense applications |
| 05/09/2002 | US20020055471 Purification step using a brominated polystyrene resin to adsorb anthocyanins |
| 05/09/2002 | US20020055469 Anticoagulants |
| 05/09/2002 | US20020055462 Use |
| 05/09/2002 | US20020055458 Method for the prevention and treatment of retinopathy |
| 05/09/2002 | US20020055457 Methods of treating cancer and the pain associated therewith using endothelin antagonists |
| 05/09/2002 | US20020055173 Plasmids for use in expressing heterologous proteins on surface viral particle and for use in gene therapy |
| 05/09/2002 | US20020055140 Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis |
| 05/09/2002 | US20020054926 Administering tobacco extract, Yerbamate extract, and extract of chewing gum and lozenges for increasing levels of norepinephrine, dopamine, and serotonin to treat psychological disorders and aid in smoking cessation |
| 05/09/2002 | US20020054923 An agent for preventing or treating hypertension, comprising a compound selected from caffeic acid, chlorogenic acid and ferulic acid or salts or esters, and a central nervous system stimulating agent; used as food and drink |
| 05/09/2002 | US20020054922 Cosmetic composition and method |
| 05/09/2002 | US20020054915 Prolonged anesthesia in joints and body spaces |
| 05/09/2002 | US20020054913 Stable drug from for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
| 05/09/2002 | US20020054911 Novel oral dosage form for carvedilol |
| 05/09/2002 | US20020054908 An oral pharmaceutical dosage from including a mixture of a delay release formulation of a non-steroidal anti-inflammatory drug and a mixture containing prostaglandin and one or more excipients |
| 05/09/2002 | US20020054907 Multiparticulate modified release composition |
| 05/09/2002 | US20020054906 Dry mix formulation for bisphosphonic acids |
| 05/09/2002 | US20020054904 Stable pergolide mesylate and process for making same |
| 05/09/2002 | US20020054903 Direct compression polymer tablet core |
| 05/09/2002 | US20020054902 Liposomes containing therapeutic genes are conjugated to targeting agents to provide transport of encapsulated gene across blood-retainal barrier and plasma membrane of ocular cell, where this gene expresses encoded therapeutical agent |
| 05/09/2002 | US20020054900 Barrier layer positioned over composite layer and being of thickness adequate to provide controlled release of bioactive agent, barrier layer being applied by low energy plasma polymerization |
| 05/09/2002 | US20020054899 Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders |
| 05/09/2002 | US20020054896 Applying onto healed wound a composition comprising a fluid, film-forming carrier, and subsequently hardening the carrier into a tangible membrane juxtaposed to the healed wound thereby reducing scarring or improving the appearance thereof |
| 05/09/2002 | US20020054895 And at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water; skin protectants |
| 05/09/2002 | US20020054887 Toxin has at least one amino acid change and is substantially non-lethal compared with wild type SPE-A toxin; for vaccines |
| 05/09/2002 | US20020054881 Variants can be used in specific immunotherapy of allergic pathologies caused by dust mites |
| 05/09/2002 | US20020054879 Reacting protein with polysaccharide to produce mixture including protein-polysaccharide conjugate and free protein |
| 05/09/2002 | US20020054871 Treating a host suffering from hyperlipidemia resulting from elevated levels of at least one of very low density lipoproteins and triglycerides and effective amount of an agent that reduces the level of active apolipoprotein E |
| 05/09/2002 | US20020054869 Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma |
| 05/09/2002 | US20020054861 Sodium lauryl ether sulfate is chosen as surfactant A, and one or more cosurfactants such as N-acylamino acids and salts, taurates, betanines etc. for reducing binding of surfactant A to the surface of the skin |
| 05/09/2002 | US20020054857 The dental formulation includes a base to which an active component vitamin C and co-enzyme Q 10 or ubiquinone are added to cure gum diseases and tooth decay |
| 05/09/2002 | US20020054856 Nicotine mucosal spray |
| 05/09/2002 | US20020054850 Monoterpenes and sesquiterpenes as chemotherapeutic sensitizers and radiation sensitizers |
| 05/09/2002 | US20020053315 Process for preparing low defect density silicon using high growth rates |
| 05/08/2002 | EP1203827A2 Polymorphisms in the human KDR gene |
| 05/08/2002 | EP1203821A2 Reductive amination of alpha-keto-dicarboxylic acids |
| 05/08/2002 | EP1203817A2 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 05/08/2002 | EP1203771A1 Remedies or preventives for frequent urination or urinary incontinence |
| 05/08/2002 | EP1203770A1 Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases |